文献速递神经核医学肿瘤 PET/CT放射性药物与辐射防护

两种PET/CT显像剂[18F]D3FSP([18F]P16-129)与[18F]AV45在阿尔茨海默病患者中的头对头比较

Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer's disease.
PubMed 文献 · EJNMMI Res · 2025-06-22

在8例临床诊断阿尔茨海默病患者中头对头比较[18F]D3FSP与[18F]AV45两种β-淀粉样蛋白PET/CT显像剂,并在6名健康受试者中进行生物分布与辐射剂量估算。结果显示两示踪剂皮层灰质平均SUVR均为1.65,全局DVR分别为1.36与1.37,SUVR与DVR均呈强相关(R²=0.8–0.9)。作者认为两者无差异、N-甲基位点氘代无获益,但[18F]D3FSP可作为Aβ PET/CT显像的备选。

要点

  • 8例阿尔茨海默病患者中,[18F]D3FSP与[18F]AV45的皮层灰质平均SUVR均为1.65。
  • 两示踪剂全局DVR分别为1.37([18F]D3FSP)与1.36([18F]AV45),SUVR与DVR相关性强(R²=0.8–0.9)。
  • 作者认为N-甲基位点氘代无获益,但[18F]D3FSP可作为Aβ PET/CT显像的备选。

核心结论

  • 结果显示[18F]D3FSP与[18F]AV45之间无差异,N-甲基位点氘代无获益。
  • 尽管如此,[18F]D3FSP的結合特征与FDA批准的[18F]AV45非常相似,可能作为脑内Aβ沉积PET/CT显像的有用备选。

研究设计与样本

  • 在8例临床诊断阿尔茨海默病患者中(平均年龄61.1±10.0岁,平均MMSE评分21±4)进行[18F]D3FSP与[18F]AV45的头对头比较。
  • 每例患者分别在数周内接受配对90分钟动态PET/CT扫描([18F]D3FSP或[18F]AV45,323±31 MBq)。
  • 另在6名健康受试者中进行生物分布研究并获得辐射剂量估算。
  • 试验注册号NCT03902548,注册日期2018年1月7日。

主要发现

  • 皮层灰质平均SUVR(50-70分钟)为[18F]AV45 1.65±0.21 vs [18F]D3FSP 1.65±0.23。
  • 全局DVR为[18F]AV45 1.36±0.14 vs [18F]D3FSP 1.37±0.13。
  • 两示踪剂间SUVR与DVR均呈强相关(R²=0.8-0.9),斜率分别约为0.9(SUVR)和约1(DVR)。
  • 与[18F]AV45相比,未见影响[18F]D3FSP视觉判读的图像伪影或混杂因素。

关键数值与推荐

  • 评估43个脑区的SUVR(50-70分钟)与分布容积比(DVR)。
  • 皮层灰质平均SUVR:[18F]AV45 1.65±0.21 vs [18F]D3FSP 1.65±0.23。
  • 全局DVR:[18F]AV45 1.36±0.14 vs [18F]D3FSP 1.37±0.13。
  • 两示踪剂SUVR与DVR的R²=0.8-0.9,斜率约0.9(SUVR)与约1(DVR)。

临床怎么用

  • 作者认为[18F]D3FSP可能作为脑内Aβ沉积PET/CT显像的有用备选。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A new β-amyloid (Aβ) targeting radiotracer, [18F]D3FSP ([18F]P16-129), for diagnosis of Alzheimer's disease (AD) is reported. This radiotracer is a deuterated N-methyl derivative of Amyvid (AV-45, florbetapir f18) which was FDA-approved in 2013. Deuteration may alter a tracer's PK such that imaging performance is improved. A head-to-head comparison between these two imaging agents was conducted in AD patients. A separate biodistribution study was conducted on six healthy subjects, and radiation dosimetry estimation was obtained. RESULTS: Eight patients, clinically diagnosed with Alzheimer's disease, had an average age of 61.1 ± 10.0 years, and an average MMSE score of 21 ± 4. Each patient underwent paired 90-minute dynamic PET/CT scans separately within a few weeks (323 ± 31 MBq of [18F]D3FSP or [18F]AV45; florbetapir f18). SUVR (50-70 min) and Distribution Volume Ratio (DVR) of 43 brain regions were evaluated. The average SUVR across cortical gray matter was 1.65 ± 0.21 for [18F]AV45 and 1.65 ± 0.23 for [18F]D3FSP, while global DVRs were 1.36 ± 0.14 and 1.37 ± 0.13 for [18F]AV45 and [18F]D3FSP respectively. Strong correlations (R2 = 0.8-0.9) were observed between tracers for both SUVR and DVR, with slopes of ~ 0.9 (SUVR) and ~ 1 (DVR). No image artifacts or confounds influenced the visual interpretation of [18F]D3FSP compared to [18F]AV45. CONCLUSIONS: Results showed no difference between [18F]D3FSP and [18F]AV45 and no benefit of deuteration at the N-methyl site. Even so, [18F]D3FSP may be a useful alternative for PET/CT imaging of Aβ deposits in the brain as its binding characteristics were very similar to its non-deuterated analog, the FDA-approved drug [18F]AV45. TRIAL REGISTRATION: Clinicaltrials.org, NCT03902548. Registered 01/07/2018.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Alexoff D, Wong DF, Kuwabara H, et al. Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer's disease. EJNMMI Res. 2025. PMID: 40544409. doi:10.1186/s13550-025-01276-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。